BriaCell Therapeutics (NASDAQ:BCTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of BriaCell Therapeutics (NASDAQ:BCTX) in a report released on Thursday, Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.17) EPS.

BriaCell Therapeutics Trading Up 2.5 %

Shares of NASDAQ BCTX opened at $0.98 on Thursday. The company has a market capitalization of $18.00 million, a price-to-earnings ratio of -0.79 and a beta of 1.34. BriaCell Therapeutics has a twelve month low of $0.46 and a twelve month high of $6.16. The business has a 50 day simple moving average of $0.71 and a 200-day simple moving average of $1.37.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BriaCell Therapeutics stock. K.J. Harrison & Partners Inc raised its stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 7.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,044 shares of the company’s stock after acquiring an additional 6,329 shares during the period. K.J. Harrison & Partners Inc owned 0.54% of BriaCell Therapeutics worth $249,000 as of its most recent SEC filing. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.